LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Cervomed Inc.
Headquarters:
Cambridge, MA, United States
Website:
https://www.cervomed.com/
Year Founded:
2010
Status:
Public
Industry Sector:
CommercialServices
CEO:
John J. Alam, MD
Number Of Employees:
15
Enterprise Value:
$-20,030,836
PE Ratio:
-4.93
Exchange/Ticker 1:
NASDAQ:CRVO
Exchange/Ticker 2:
N/A
Latest Market Cap:
$89,202,904
BioCentury
|
Nov 19, 2024
Product Development
An understudied dementia soon to get a pair of Phase II readouts
CervoMed and Cognition Therapeutics testing different therapeutic hypotheses in dementia with Lewy bodies
Read More
BioCentury
|
May 20, 2024
Management Tracks
Chroma hires Jenny Marlowe as CDO
Plus: William Elder named CFO of CervoMed, and updates from Xspray and Senti
Read More
BioCentury
|
Apr 2, 2024
Product Development
Neurology’s false choice: symptomatic vs. disease-modifying
A new theme in Alzheimer’s is aiming for early symptom relief PLUS long-term disease modification
Read More
BioCentury
|
Mar 29, 2024
Finance
Public equity report: Avalo gets makeover with PIPE, acquisition
Plus: A PIPE for CervoMed ahead of dementia readout; and Stoke, Praxis follow clinical readouts with opportunistic follow-ons
Read More
Items per page:
10
1 - 4 of 4